NOTE 5 - CAPITAL STOCK	9 Months Ended
Mar. 31, 2020
Notes
NOTE 5 - CAPITAL STOCK	NOTE 5 – STOCKHOLDERS’ DEFICT Preferred Stock – The Company is authorized to issue 10,000,000 shares of preferred stock. No preferred stock has been issued to date. The authorized preferred shares are non-voting and the Board of Directors has not designated any liquidation value or dividend rates. Common Stock – The Company is authorized to issue 250,000,000 shares of no - par value common stock. The holders of the Company's common stock are entitled to one vote for each share held of record on all matters to be voted on by those stockholders. As of March 31, 2020, and June 30, 2019, the Company had 202,783,598 shares and 199,295,503 shares of common stock issued and 202,729,842 and 199,241,747 shares outstanding, respectively. During the nine - months ended March 31, 2020, the Company issued 2,238,095 shares of common stock to one individual for obtaining a settlement in a patent matter at $44,762 ($0.0200 per share). The company recorded an accrual in the amount of $38,048 in the annual financial statements ended June 30, 2019. An additional loss of $6,714 was recorded during the nine - months ended March 31, 2020. During the nine - months ended March 31, 2020, the Company sold 1,250,000 shares of its common stock for approximately $11,055 in cash proceeds to one individual at price of approximately $ 0.009 per share. Treasury Stock - The Company holds 53,756 of its common stock as treasury stock, which is valued at cost of $19,387 at March 31, 2020. Stock – based Compensation - On October 22, 2008 the Company adopted the 2008 Amended and Restated Long-Term Equity Incentive Plan, whereby the Board was authorized to issue up to 10,000,000 shares of common stock (including incentive stock options) to certain eligible employees, directors, and consultants of the Company or its subsidiaries. The term of the plan was 10 years. It expired in October 2018.

NOTE 5 - CAPITAL STOCK

9 Months Ended

Mar. 31, 2020

NOTE 5 – STOCKHOLDERS’ DEFICT

Preferred Stock – The Company is authorized to issue 10,000,000 shares of preferred stock. No preferred stock has been issued to date. The authorized preferred shares are non-voting and the Board of Directors has not designated any liquidation value or dividend rates.

Common Stock – The Company is authorized to issue 250,000,000 shares of no - par value common stock. The holders of the Company's common stock are entitled to one vote for each share held of record on all matters to be voted on by those stockholders. As of March 31, 2020, and June 30, 2019, the Company had 202,783,598 shares and 199,295,503 shares of common stock issued and 202,729,842 and 199,241,747 shares outstanding, respectively.

During the nine - months ended March 31, 2020, the Company issued 2,238,095 shares of common stock to one individual for obtaining a settlement in a patent matter at $44,762 ($0.0200 per share). The company recorded an accrual in the amount of $38,048 in the annual financial statements ended June 30, 2019. An additional loss of $6,714 was recorded during the nine - months ended March 31, 2020.

During the nine - months ended March 31, 2020, the Company sold 1,250,000 shares of its common stock for approximately $11,055 in cash proceeds to one individual at price of approximately $ 0.009 per share.

Treasury Stock - The Company holds 53,756 of its common stock as treasury stock, which is valued at cost of $19,387 at March 31, 2020.

Stock – based Compensation - On October 22, 2008 the Company adopted the 2008 Amended and Restated Long-Term Equity Incentive Plan, whereby the Board was authorized to issue up to 10,000,000 shares of common stock (including incentive stock options) to certain eligible employees, directors, and consultants of the Company or its subsidiaries. The term of the plan was 10 years. It expired in October 2018.